{{Rsnum
|rsid=1406428
|Gene=CEACAM3
|Chromosome=2
|position=51509856
|Orientation=plus
|GMAF=0.2562
|Gene_s=CEACAM3
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 78.5 | 20.0 | 1.5
| HCB | 35.6 | 51.1 | 13.3
| JPT | 29.5 | 59.1 | 11.4
| YRI | 50.8 | 44.4 | 4.8
| ASW | 0.0 | 0.0 | 0.0
| CHB | 35.6 | 51.1 | 13.3
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=22491018
|Trait=None
|Title=Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis.
|RiskAllele=
|Pval=2E-7
|OR=2.7400
|ORtxt=None
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}